WOCKPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.0
| Stock Code | WOCKPHARMA | Market Cap | 22,038 Cr. | Current Price | 1,354 ₹ | High / Low | 1,870 ₹ |
| Stock P/E | 156 | Book Value | 178 ₹ | Dividend Yield | 0.00 % | ROCE | 4.40 % |
| ROE | -0.53 % | Face Value | 5.00 ₹ | DMA 50 | 1,389 ₹ | DMA 200 | 1,396 ₹ |
| Chg in FII Hold | -0.10 % | Chg in DII Hold | -0.45 % | PAT Qtr | 54.0 Cr. | PAT Prev Qtr | 69.0 Cr. |
| RSI | 44.3 | MACD | -10.6 | Volume | 2,96,318 | Avg Vol 1Wk | 3,51,426 |
| Low price | 1,110 ₹ | High price | 1,870 ₹ | PEG Ratio | 6.47 | Debt to equity | 0.76 |
| 52w Index | 32.1 % | Qtr Profit Var | 250 % | EPS | 8.68 ₹ | Industry PE | 29.0 |
📊 Chart Patterns & Trend: WOCKPHARMA is trading below both its 50 DMA (1,389 ₹) and 200 DMA (1,396 ₹), indicating bearish pressure. Price action suggests consolidation between 1,320–1,390 ₹, with strong support at 1,320–1,340 ₹ and resistance near 1,390–1,420 ₹. Trendlines show sideways movement with bearish undertone.
📈 Moving Averages: Current price (1,354 ₹) is below both 50 DMA and 200 DMA, signaling weakness. A sustained move above 1,390–1,420 ₹ is required for reversal confirmation.
📉 RSI: At 44.3, RSI is neutral-to-weak, suggesting limited momentum and possible consolidation.
📉 MACD: Negative at -10.6, confirming bearish momentum in the short term.
📊 Bollinger Bands: Price is near the lower band, indicating oversold conditions and potential support around 1,320–1,340 ₹.
📊 Volume Trends: Current volume (2,96,318) is below the 1-week average (3,51,426), showing weak participation and lack of strong buying interest.
🎯 Entry Zone: 1,320–1,340 ₹ (near support, risk-managed entry).
🎯 Exit Zone: 1,390–1,420 ₹ (resistance zone, profit booking advisable).
📌 Momentum Signal: Weak short-term momentum, consolidation phase with bearish undertone. A breakout above 1,420 ₹ is needed to confirm reversal toward 1,500–1,600 ₹.
Positive
- EPS of 8.68 ₹ reflects earnings base.
- Quarterly profit variation (+250%) highlights strong operational improvement.
- 52-week index return of 32.1% shows sector momentum.
Limitation
- High P/E (156) compared to industry average (29.0) suggests extreme overvaluation.
- Weak ROCE (4.40%) and negative ROE (-0.53%) highlight poor efficiency.
- PEG ratio of 6.47 indicates expensive growth prospects.
- Debt-to-equity ratio of 0.76 shows high leverage risk.
Company Negative News
- Decline in FII holdings (-0.10%) and DII holdings (-0.45%) shows reduced institutional confidence.
- Sequential PAT decline from 69 Cr. to 54 Cr. highlights margin pressure.
Company Positive News
- Quarterly profit variation (+250%) indicates strong rebound compared to prior periods.
Industry
- Industry P/E at 29.0 indicates sector is moderately valued compared to the company’s extreme valuation.
- 52-week index return of 32.1% shows healthy sector performance.
Conclusion
⚖️ WOCKPHARMA is consolidating near support with weak momentum and bearish undertones. Entry near 1,320–1,340 ₹ offers limited risk, while exits should be considered around 1,390–1,420 ₹ unless strong reversal occurs. Fundamentally overvalued with weak efficiency metrics, making it a cautious technical play despite recent profit rebound.